HUTCHMED (China) Limited ( (HK:0013) ) just unveiled an update.
HUTCHMED (China) Limited has appointed Mr. Alvin Wong as an Independent Non-executive Director and a member of the Audit Committee, effective March 6, 2025. Mr. Wong brings over 35 years of experience in accounting, auditing, and corporate finance, having played key roles in stock exchange listings and mergers and acquisitions. This strategic appointment is expected to enhance HUTCHMED’s financial stewardship and support its growth initiatives.
More about HUTCHMED (China) Limited
HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on the discovery, global development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company has successfully marketed its first three medicines in China, with one also approved in the US, Europe, and Japan.
YTD Price Performance: 6.81%
Average Trading Volume: 52,318
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £2.2B
Learn more about 0013 stock on TipRanks’ Stock Analysis page.